OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	144
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	61
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	60
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	55
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance	54
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	38
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	36
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	35
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	35
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?	32
Guidance for interactions between antiseizure medications	28
Hormones, microbes, and PrEP drugs in the female genital tract	27
Comorbidities and the right dose: antipsychotics	27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	26
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	24
Bioactivity descriptors for in vivo toxicity prediction: now and the future	23
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	23
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	23
A comprehensive review of the efficacy and safety of ertugliflozin	22
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	21
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	20
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	19
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	18
Impact of sex and gender medicine on antibiotic research and use: a narrative review of existing evidence	18

Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	17
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	17
Correction	17
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	16
Development and hepatotoxicity of rifamycin derivatives	16
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	15
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	15
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	15
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	15
Drug-drug interactions between psychotropic medications and oral contraceptives	14
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	14
Potential integration of multiple organs-on-a-chip for comprehensive drug–drug interaction prediction	14
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	14
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	14
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	14
Clinically significant interactions between drugs, microbiome, and sex	13
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	13
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	13
Risk factors and prediction for DILI in clinical practice	13
Pregnancy and epilepsy: pharmacokinetic insights into antiseizure medications	13
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	13
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	12
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	12
Understanding pharmacokinetic variability in women across different life stages	12
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	12
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	12
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	12
Population pharmacokinetic–pharmacodynamic analysis of givinostat	12
Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment	12
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	12
PBPK models of the female reproductive tract: current and future analysis	11
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	11
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	11
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	10
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	10
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	10
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	10
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	10
Switching from cangrelor to oral P2Y ₁₂ inhibitors: a focused review on drug–drug interactions	10
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	10
Rivaroxaban vs. apixaban in short bowel syndrome: a focused clinical pharmacology review	10
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	10
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	10
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	10
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	9
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	9
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	9
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	9

Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	9
Drug interactions in people with HIV treated with antivirals for other viral illnesses	9
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	9
Overcoming barriers to machine learning applications in toxicity prediction	9
An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications	9
Sex differences and impact of age-based menopausal status on tacrolimus pharmacokinetics: results of the TransplantLines biobank and cohort study	9
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	9
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	9
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?	8
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	8
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	8
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	8
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	8
DILI prediction in drug development: present and future	8
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	8
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	8
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	8
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	8
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	8
Drug–drug interactions in HIV-infected patients receiving chemotherapy	8
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	8
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	8
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	8
Psychedelics, psychiatry and pharmacokinetics - where are we now?	8